Biocon Biologics allots equity shares worth Rs 2,205.63 crore to its parent

At the time of announcing the deal to acquire Viatris, BBL had said it would be through a cash payment of USD 2 billion, which would be funded through USD 800 million raised through equity infusion in BBL and the remainder by debt, additional equity or a combination

Biocon Biologics allots equity shares worth Rs 2,205.63 crore to its parent
At the time of announcing the deal to acquire Viatris, BBL had said it would be through a cash payment of USD 2 billion, which would be funded through USD 800 million raised through equity infusion in BBL and the remainder by debt, additional equity or a combination